252 related articles for article (PubMed ID: 26387039)
41. Reduced Erlotinib sensitivity of epidermal growth factor receptor-mutant non-small cell lung cancer following cisplatin exposure: a cell culture model of second-line erlotinib treatment.
Chin TM; Quinlan MP; Singh A; Sequist LV; Lynch TJ; Haber DA; Sharma SV; Settleman J
Clin Cancer Res; 2008 Nov; 14(21):6867-76. PubMed ID: 18980981
[TBL] [Abstract][Full Text] [Related]
42. Results from a single institution phase II trial of concurrent docetaxel/carboplatin/radiotherapy followed by surgical resection and consolidation docetaxel/carboplatin in stage III non-small-cell lung cancer.
Das M; Donington JS; Murphy J; Kozak M; Eclov N; Whyte RI; Hoang CD; Zhou L; Le QT; Loo BW; Wakelee H
Clin Lung Cancer; 2011 Sep; 12(5):280-5. PubMed ID: 21752720
[TBL] [Abstract][Full Text] [Related]
43. Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy.
Sunaga N; Tomizawa Y; Yanagitani N; Iijima H; Kaira K; Shimizu K; Tanaka S; Suga T; Hisada T; Ishizuka T; Saito R; Dobashi K; Mori M
Lung Cancer; 2007 Jun; 56(3):383-9. PubMed ID: 17368623
[TBL] [Abstract][Full Text] [Related]
44. Single-agent gefitinib with concurrent radiotherapy for locally advanced non-small cell lung cancer harboring mutations of the epidermal growth factor receptor.
Okamoto I; Takahashi T; Okamoto H; Nakagawa K; Watanabe K; Nakamatsu K; Nishimura Y; Fukuoka M; Yamamoto N
Lung Cancer; 2011 May; 72(2):199-204. PubMed ID: 20828860
[TBL] [Abstract][Full Text] [Related]
45. Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by high dose three-dimension conformal thoracic radiotherapy (74 Gy) with concurrent carboplatin, paclitaxel, and gefitinib in unresectable stage IIIA and stage IIIB non-small cell lung cancer.
Stinchcombe TE; Morris DE; Lee CB; Moore DT; Hayes DN; Halle JS; Rivera MP; Rosenman JG; Socinski MA
J Thorac Oncol; 2008 Mar; 3(3):250-7. PubMed ID: 18317067
[TBL] [Abstract][Full Text] [Related]
46. Prospective study of epidermal growth factor receptor tyrosine kinase inhibitors concurrent with individualized radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer.
Wang J; Xia TY; Wang YJ; Li HQ; Li P; Wang JD; Chang DS; Liu LY; Di YP; Wang X; Wu WZ
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):e59-65. PubMed ID: 21345607
[TBL] [Abstract][Full Text] [Related]
47. A phase I trial of gefitinib and nimotuzumab in patients with advanced non-small cell lung cancer (NSCLC).
Kim SH; Shim HS; Cho J; Jeong JH; Kim SM; Hong YK; Sung JH; Ha SJ; Kim HR; Chang H; Kim JH; Tania C; Cho BC
Lung Cancer; 2013 Mar; 79(3):270-5. PubMed ID: 23261229
[TBL] [Abstract][Full Text] [Related]
48. Phase II study of concurrent thoracic radiotherapy in combination with weekly paclitaxel plus carboplatin in locally advanced non-small cell lung cancer: LOGIK0401.
Takayama K; Inoue K; Tokunaga S; Matsumoto T; Oshima T; Kawasaki M; Imanaga T; Kuba M; Takeshita M; Harada T; Shioyama Y; Nakanishi Y
Cancer Chemother Pharmacol; 2013 Dec; 72(6):1353-9. PubMed ID: 24166107
[TBL] [Abstract][Full Text] [Related]
49. Autophagy Inhibition Overcomes the Antagonistic Effect Between Gefitinib and Cisplatin in Epidermal Growth Factor Receptor Mutant Non--Small-Cell Lung Cancer Cells.
Liu JT; Li WC; Gao S; Wang F; Li XQ; Yu HQ; Fan LL; Wei W; Wang H; Sun GP
Clin Lung Cancer; 2015 Sep; 16(5):e55-66. PubMed ID: 25979647
[TBL] [Abstract][Full Text] [Related]
50. Preoperative concurrent chemoradiotherapy of S-1/cisplatin for stage III non-small cell lung cancer.
Yamaguchi M; Toyokawa G; Ohba T; Sasaki T; Kometani T; Hamatake M; Hirai F; Taguchi K; Yamanaka T; Seto T; Takenoyama M; Sugio K; Ichinose Y
Ann Thorac Surg; 2013 Nov; 96(5):1783-9. PubMed ID: 23998404
[TBL] [Abstract][Full Text] [Related]
51. Detection of epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small-cell lung cancer.
He C; Liu M; Zhou C; Zhang J; Ouyang M; Zhong N; Xu J
Int J Cancer; 2009 Nov; 125(10):2393-9. PubMed ID: 19530244
[TBL] [Abstract][Full Text] [Related]
52. A phase II trial of gefitinib monotherapy in chemotherapy-naïve patients of 75 years or older with advanced non-small cell lung cancer.
Ebi N; Semba H; Tokunaga SJ; Takayama K; Wataya H; Kuraki T; Yamamoto H; Akamine SJ; Okamoto I; Nakanishi Y;
J Thorac Oncol; 2008 Oct; 3(10):1166-71. PubMed ID: 18827614
[TBL] [Abstract][Full Text] [Related]
53. Prospective assessment of pemetrexed or pemetrexed plus platinum in combination with gefitinib or erlotinib in patients with acquired resistance to gefitinib or erlotinib: a phase II exploratory and preliminary study.
Yu S; Zhang B; Xiang C; Shu Y; Wu H; Huang X; Yu Q; Yin Y; Guo R
Clin Lung Cancer; 2015 Mar; 16(2):121-7. PubMed ID: 25450874
[TBL] [Abstract][Full Text] [Related]
54. Direct comparison of 3 PCR methods in detecting EGFR mutations in patients with advanced non-small-cell lung cancer.
Ikeda T; Nakamura Y; Yamaguchi H; Tomonaga N; Doi S; Nakatomi K; Iida T; Motoshima K; Mizoguchi K; Nagayasu T; Tsukamoto K; Kohno S
Clin Lung Cancer; 2012 Sep; 13(5):369-74. PubMed ID: 22410386
[TBL] [Abstract][Full Text] [Related]
55. Thoracic radiotherapy and concurrent almonertinib for unresectable stage III EGFR-mutated non-small-cell lung cancer: a phase 2 study.
Zhu L; Zou C; Zhang Z; Wang J; Yang L; Rao C; Yang Z; Liang J; Xia B; Shenglin MA
BMC Cancer; 2021 May; 21(1):511. PubMed ID: 33962566
[TBL] [Abstract][Full Text] [Related]
56. Phase 2 Study of Nimotuzumab in Combination With Concurrent Chemoradiotherapy in Patients With Locally Advanced Non-Small-Cell Lung Cancer.
Yamamoto N; Harada H; Okamoto I; Masuda N; Hayakawa K; Satouchi M; Soejima T; Nishio M; Kozuka T; Takeda K; Tanaka M; Seto T; Sasaki T; Tsubouchi H; Kakurai Y; Nishimura Y; Nakagawa K
Clin Lung Cancer; 2021 Mar; 22(2):134-141. PubMed ID: 33518480
[TBL] [Abstract][Full Text] [Related]
57. EGFR kinase domain mutation positive lung cancers are sensitive to intrapleural perfusion with hyperthermic chemotherapy (IPHC) complete treatment.
Zhang H; Zhan C; Ke J; Xue Z; Zhang A; Xu K; Shen Z; Yu L; Chen L
Oncotarget; 2016 Jan; 7(3):3367-78. PubMed ID: 26654941
[TBL] [Abstract][Full Text] [Related]
58. Treatment Design and Rationale for a Randomized Trial of Cisplatin and Etoposide Plus Thoracic Radiotherapy Followed by Nivolumab or Placebo for Locally Advanced Non-Small-Cell Lung Cancer (RTOG 3505).
Gerber DE; Urbanic JJ; Langer C; Hu C; Chang IF; Lu B; Movsas B; Jeraj R; Curran WJ; Bradley JD
Clin Lung Cancer; 2017 May; 18(3):333-339. PubMed ID: 27923550
[TBL] [Abstract][Full Text] [Related]
59. The impact of epidermal growth factor receptor mutations on patterns of disease recurrence after chemoradiotherapy for locally advanced non-small cell lung cancer: a literature review and pooled analysis.
Ochiai S; Nomoto Y; Watanabe Y; Yamashita Y; Toyomasu Y; Kawamura T; Takada A; Noriko ; Sakuma H
J Radiat Res; 2016 Sep; 57(5):449-459. PubMed ID: 27534790
[TBL] [Abstract][Full Text] [Related]
60. Induction chemotherapy followed by gefitinib and concurrent thoracic radiotherapy for unresectable locally advanced adenocarcinoma of the lung: a multicenter feasibility study (JCOG 0402).
Niho S; Ohe Y; Ishikura S; Atagi S; Yokoyama A; Ichinose Y; Okamoto H; Takeda K; Shibata T; Tamura T; Saijo N; Fukuoka M
Ann Oncol; 2012 Sep; 23(9):2253-2258. PubMed ID: 22357446
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
